Icon

Zeposia - (0.23, 0.46, and 0.92 mg ; Capsule)

Ozanimod Hydrochloride BRISTOL MYERS SQUIBB
0.23, 0.46, and 0.92 mg ; Capsule
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
None None
ZEPOSIA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of: • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. • Moderately to severely active ulcerative colitis (UC) in adults.
Yes
Zeposia Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
******* ****** **** *** **** *** **** *** **** *** **** ** *** **, ****
****** *** ********* *** ********* *** ********* *** ********* **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* ****** *** \ ********* **** **, **** ******* **** *** ****** **** ****
****** *** \ ********* **** **, **** ******* **** *** ****** **** ****
  1. *** **, **** : * **** ** ** ***** *** ***** *** ***** ****.
  2. *** **, **** : ******* ******** *** ***** *** **** ** ******.
  3. *** *, **** : ****** ******** *** ***** *** **** ** ******.
  4. *** *, **** : *** **** ******* **** ************ ** ****** **. '***.
  5. *** **, **** : *** **** ****** **** ************ ** ****** **. '***.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.